Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide

Gene Therapy

Volumn 11, Issue 13, 2004, Pages 1087-1098

  Argnani, Rafaela ^a   Boccafogli, Luca ^a   Marconi, Peggy C ^a   Manservigi, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

HBV; HSV; Targeting; Viral vectors

Indexed keywords

HEPARAN SULFATE; PROTEIN C; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VECTOR; GLYCOPROTEIN GC, HERPES SIMPLEX VIRUS TYPE 1; HEPATITIS B SURFACE ANTIGEN; HYBRID PROTEIN; PRESURFACE PROTEIN 1, HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR; VIRUS ENVELOPE PROTEIN;

ARTICLE; BINDING AFFINITY; BIOENGINEERING; CELL SPECIFICITY; CELL STRAIN HEPG2; CONTROLLED STUDY; GENE TRANSFER; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR BINDING; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; VIRUS INFECTIVITY; ANIMAL; CERCOPITHECUS; GENE DELETION; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROTEIN BINDING; TUMOR CELL LINE; VERO CELL;

HEPATITIS B VIRUS; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; GENE DELETION; GENETIC ENGINEERING; GENETIC VECTORS; HEPATITIS B SURFACE ANTIGENS; HEPATOCYTES; HERPESVIRUS 1, HUMAN; HUMANS; PROTEIN BINDING; PROTEIN PRECURSORS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 3242777021     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302266     Document Type: Article

References (60)

1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
2. Kootstra NA, Verma IM. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 2003; 43: 413-439.
3. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003; 21: 117-122.
4. Mah C, Byrne BJ, Flotte TR. Virus-based gene delivery systems. Clin Pharmacokinet 2002; 41: 901-911.
5. Robbins PD, Tahara H, Ghivizzani SC. Viral vectors for gene therapy. Trends Biotechnol 1998; 16: 35-40.
6. Advani SJ, Weichselbaum RR, Whitley RJ, Roizman B. Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect 2002; 8: 551-563.
7. Anderson DB et al. Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol 2000; 74: 2481-2487.
8. Burton EA, Bai Q, Goins WF, Glorioso JC. Targeting gene expression using HSV vectors. Adv Drug Deliv Rev 2001; 53: 155-170.
9. Douglas JT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
10. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995; 92: 9747-9751.
11. Laquerre S, Anderson DB, Stolz DB, Glorioso JC. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 1998; 72: 9683-9697.
12. Nicklin SA, Baker AH. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy Curr Gene Ther 2002; 2: 273-293.
13. Valsesia-Wittmarm S et al. Modification in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994; 68: 4609-4619.
14. Aw MM, Dhawan A. Acute liver failure. Indian J Pediatr 2002; 69: 87-91.
15. Clayton PT. Inborn errors presenting with liver dysfunction. Semin Neonatol 2002; 7: 49-63.
16. Stecenko AA, Brigham KL. Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Therapy 2003; 10: 95-99.
17. Kobayashi S et al. Gene transfer into the liver by plasmid injection into the portal vein combined with electroporation. J Gene Med 2003; 5: 201-208.
18. Cheung ST et al. Liver as an ideal target for gene therapy: expression of CTLA4Ig by retroviral gene transfer. J Gastroenterol Hepatol 2002; 17: 1008-1014.
19. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998; 9: 1975-1981.
20. Fong Y et al. Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors. Hepatology 1995; 22: 723-729.
21. Forbes SJ et al. Retroviral gene transfer to the liver in vivo during tri-iodothyronine inducing hyperplasia. Gene Therapy 1998; 5: 552-555.
22. Fraefel C et al. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 1997; 3: 813-825.
23. Guha C, Roy-Chowdhury N, Jauregui H, Roy-Chowdhury J. Hepatocyte-based gene therapy. J Hepatobiliary Pancreat Surg 2001; 8: 51-57.
24. Gupta S, Malhi H, Gagandeep S, Novikoff P. Liver repopulation with hepatocyte transplantation: new avenues for gene and cell therapy. J Gene Med 1999; 1: 386-392.
25. Ido A et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by o hypoxia-inducible enhancer linked to a human á-fetoprotein promoter. Cancer Res 2001; 61: 3016-3021.
26. Jarnagin WR et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003; 10: 215-223.
27. Kosai KI et al. Retrovirus-mediated in vivo gene transfer in the replicating liver using recombinant hepatocyte growth factor without liver injury or partial hepatectomy. Hum Gene Ther 1998; 9: 1293-1301.
28. Kren BT, Chowdhury NR, Chowdhury JR, Steer CJ. Gene therapy as an alternative to liver transplantation. Liver Transplant 2002; 8: 1098-1108.
29. Lu B, Gupta S, Federoff H. Ex vivo hepatic gene transfer in mouse using a defective herpes simplex virus-1 vector. Hepatology 1995; 21: 752-759.
30. Pichard V, Aubert D, Ferry N. Efficient retroviral gene transfer to the liver in vivo using nonpolypeptidic mitogens. Biochem Biophys Res Commun 2001; 286: 929-935.
31. Fraefel C, Jacoby DR, Breakefield XO. Herpes simplex virus type 1-based amplicon vector systems. Adv Virus Res 2000; 55: 425-451.
32. Glorioso JC et al. Engineering herpes simplex virus vectors for human gene therapy Adv Pharmacol 1997; 40: 103-136.
33. Latchman DS. Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene 2001; 264: 1-9.
34. Link CJ, Vahanian NN, Wang S. Herpes simplex amplicon vectors. Methods Mol Med 2003; 76: 61-87.
35. Burton EA, Bai Q, Goins WE, Glorioso JC. Replication-defective genomic herpes simplex vectors: design and production. Curr Opin Biotechnol 2002; 13: 424-428.
36. Krisky DM et al. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Therapy 1998; 5: 1517-1530.
37. Krisky DM et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Therapy 1998; 5: 1593-1603.
38. Chung SM et al. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Therapy 2002; 9: 75-80.
39. Markovitz NS, Roizman B. Replication-competent herpes simplex viral vectors for cancer therapy. Adv Virus Res 2000; 55: 409-424.
40. Pawlik TM et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95: 1171-1181.
41. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin Invest Drugs 2000; 9: 311-327.
42. Laquerre S et al. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contribution to virus attachment, penetration, and cell-to-cell spread. J Virol 1998; 72: 6119-6130.
43. Shukla D et al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry Cell 1999; 99: 13-22.
44. Montgomery RI, Warner MS, Brian JL, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427-436.
45. Krummenacher C et al. The first immunoglobulin-like domain of HveC is sufficient to bind herpes simplex virus gD with full affinity, while the third domain is involved in oligomerization of HveC. J Virol 1999; 73: 8127-8137.
46. Cai W, Gu B, Person S. Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J Virol 1988; 62: 2596-2604.
47. Desai P, Homa FL, Person S, Glorioso JC. Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity. J Virol 1988; 69: 1147-1156.
48. Dingwell KS et al. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junction of cultured cells. J Virol 1994; 68: 834-845.
49. Ligas MW, Johnson DC. A herpes simplex virus mutant in which glycoprotein D sequences are replaced by β-galactosidase sequences binds to but is unable to penetrate into cells. J Virol 1988; 62: 1486-1494.
50. Roop C, Hutchinson L, Johnson DC. A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H. J Virol 1993; 67: 2285-2297.
51. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986; 46: 429-436.
52. Neurath AR, Strick N. The putative cell receptor for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBV. Virology 1994; 204: 475-477.
53. Petit MA et al. HepG2 cell binding activities of different hepatitis B virus isolates: inhibitory effect of anti-HBs and anti-preS1 (21-47), Virology 1991; 180: 483-491.
54. Petit MA, Capel F, Dubanchet S, Mabit H. PreS1-specific binding proteins as potential receptors for hepatitis B virus in human hepatocytes. Virology 1992; 187: 211-222.
55. Fink RJ, Eisenberg RJ, Cohen GH, Wagner EK. Detailed analysis of the portion of the herpes simplex virus type 1 genome encoding glycoprotein C. J Virol 1983; 45: 634-647.
56. Mardberg K, Trybala E, Glorioso JC, Bergstrom T. Mutational analysis of heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C. J Gen Virol 2001; 82: 1941-1950.
57. Dolter KE, King SR, Holland TC. Incorporation of CD4 into virions by recombinant herpes simplex virus. J Virol 1993; 67: 189-195.
58. Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Rα2 receptor for cell entry and independent of glycoprotein D receptor interactions. Proc Natl Acad Sci USA 2002; 99: 15124-15129.
59. Dutch RE, Bagai Joshi S, Lamb RA. Membrane fusion promoted by increasing surface densities of the paramyxovirus F and HN proteins: comparison of fusion reactions mediated by simian virus 5 F, human parainfluenza virus type 3 F, and influenza virus HA. J Virol 1988; 72: 7745-7753.
60. Takai E et al. A solid-phase enzyme immunoassay for the determination of IgM and IgG antibodies against translation products of pre-S1 and pre-S2 regions of hepatitis B virus. J Immunol Methods 1986; 95: 23-30.